Can You Microdose Wegovy — and Should You?

You've read online that some people inject less than their prescribed dose, here's what that actually means

The term 'microdosing Wegovy' comes mostly from social media, where people share experiences of drawing a smaller amount from the pen, or injecting only part of their weekly dose to manage side effects, and what microdosing Wegovy actually involves is worth understanding before drawing any conclusions. It sounds reasonable on the surface, if 0.5 mg causes nausea, surely 0.25 mg would be easier to tolerate?

The problem is that Wegovy pens are pre-filled and pre-set. Each pen delivers one fixed dose; there is no dial or mechanism to draw a partial amount. Attempting to extract a partial dose risks incorrect dosing, contamination, and damage to the needle mechanism. The NHS semaglutide patient information page is clear that the pen should be used exactly as directed, with no dose adjustment except on a prescriber's instruction.

What people sometimes call 'microdosing' is also distinct from dose delays, which a prescriber can legitimately recommend when someone needs more time at a lower step before moving up. These are not the same thing, and conflating them is where a lot of online confusion starts.

If you're exploring what this practice involves and whether it could apply to you, the full breakdown of what counts as a microdose of Wegovy covers the terminology in more depth.

Why the titration schedule already solves the problem microdosing is trying to fix

The licensed schedule for Wegovy begins at 0.25 mg, a dose chosen specifically for tolerability, not for weight-loss effect. Most people will not see significant weight loss at this level. Its job is to let your system adjust before the therapeutic doses begin. The prescriber then moves the dose up in roughly four-week steps: 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg maintenance, with the newer 7.2 mg pen available for those who progress to the highest level.

That slow ramp is the clinical answer to the tolerability question microdosing is trying to address. If nausea or other GI effects are troublesome at a given step, a prescriber can hold the dose there for an additional four weeks before increasing. That extended-stay option is documented, clinically reviewed, and keeps the medicine within its licence. It achieves exactly what informal microdosing claims to achieve, without the risks of an unlicensed, self-managed approach.

The STEP 1 trial (which used the 2.4 mg maintenance dose and was published in the New England Journal of Medicine) reported around 15% average body weight reduction at 68 weeks. Those results were achieved on the licensed schedule, not on improvised lower doses. If you are asking whether Wegovy can be microdosed, there is no equivalent trial data for sub-licensed semaglutide dosing in weight management to support it.

For a broader look at how semaglutide works and what the evidence covers, the semaglutide overview sets out the full picture.

What to do instead, and how a prescriber can actually help

If side effects are driving the question about microdosing, that conversation belongs with your prescriber, not with a Reddit thread. A GPhC-registered Independent Prescriber can extend your time at the current dose, review whether a temporary reduction to the previous step is appropriate, or help identify whether the side effects are manageable with simple practical adjustments, drinking enough water, eating smaller portions, avoiding fatty foods in the first weeks.

Many people find the worst GI symptoms settle within the first ten to fourteen days of a new dose. Getting through a Monday evening of mild nausea before the school run on Tuesday is genuinely unpleasant; it is also, for most people, temporary. That context matters when deciding whether to deviate from the licensed schedule.

Adjusting your own dose outside a clinical review carries real risks: too little semaglutide may mean the appetite-regulating effect never properly establishes; self-manipulation of a pre-set pen risks inaccurate dosing or contamination; and using the medicine in a way that departs from its licence means your prescriber cannot properly supervise your care.

There is a related but separate question about whether the idea of proposed benefits of lower semaglutide doses has any emerging research behind it, some early studies exist, but none in the context of licensed weight management in the UK. For anyone who has decided they want to microdose semaglutide, the answer under UK prescribing practice remains that your prescriber manages your dose, and that is the right starting point for the conversation. If the current dose is not working for you, that is a clinical conversation, you can reach our support team or start a new consultation through our treatment page.